ICON Public (NASDAQ:ICLR) Lowered to Neutral Rating by JPMorgan Chase & Co.

ICON Public (NASDAQ:ICLR) was downgraded by investment analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued on Tuesday,Briefing.com Automated Import reports. They currently have a $150.00 price target on the medical research company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 3.45% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the company. TD Cowen downgraded ICON Public from a “buy” rating to a “hold” rating and cut their price target for the company from $254.00 to $157.00 in a research note on Monday, April 14th. Barclays restated an “equal weight” rating and set a $165.00 price objective (down from $240.00) on shares of ICON Public in a research report on Thursday, April 10th. Citigroup reduced their price target on shares of ICON Public from $290.00 to $215.00 and set a “buy” rating on the stock in a report on Monday, April 7th. Mizuho reduced their price target on shares of ICON Public from $238.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. Finally, William Blair restated an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $223.08.

ICON Public Price Performance

NASDAQ ICLR opened at $145.00 on Tuesday. ICON Public has a one year low of $133.28 and a one year high of $347.72. The stock has a 50-day moving average of $169.25 and a 200 day moving average of $198.88. The company has a market capitalization of $11.71 billion, a price-to-earnings ratio of 15.22, a PEG ratio of 1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. On average, sell-side analysts forecast that ICON Public will post 13.38 EPS for the current year.

Institutional Trading of ICON Public

Institutional investors have recently made changes to their positions in the business. Sierra Ocean LLC acquired a new stake in shares of ICON Public in the 4th quarter worth $29,000. Park Place Capital Corp boosted its position in shares of ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after purchasing an additional 166 shares in the last quarter. Private Trust Co. NA boosted its position in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after purchasing an additional 82 shares in the last quarter. NBC Securities Inc. acquired a new stake in shares of ICON Public in the 1st quarter worth $59,000. Finally, GAMMA Investing LLC boosted its position in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.